Durvalumab (anti-PD-L1)
Product Specifications
UNSPSC Description
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity[1][2].
Target Antigen
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/durvalumab-anti-pd-l1.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Durvalumab (anti-PD-L1)]
References & Citations
[1]Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.|[2]Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P9919A/Durvalumab-anti-PD-L1-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P9919A/Durvalumab-anti-PD-L1-SDS-MedChemExpress.pdf
Clinical Information
Phase 4
CAS Number
9007-83-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
OR1007100-01 100 mg
3,5-Bis ((((9H-fluoren-9-yl) methoxy) carbonyl) amino) benzoic acid
Ask
View Details OR1007100-02 250 mg
3,5-Bis ((((9H-fluoren-9-yl) methoxy) carbonyl) amino) benzoic acid
Ask
View Details 
OR1007100-03 1 g
3,5-Bis ((((9H-fluoren-9-yl) methoxy) carbonyl) amino) benzoic acid
Ask
View Details OR1007100-04 5 g
3,5-Bis ((((9H-fluoren-9-yl) methoxy) carbonyl) amino) benzoic acid
Ask
View Details 